Latest News
-
29th September 2025
Executive and Non-Executive Board Changes
-
25th September 2025
Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million
-
4th September 2025
Arecor announces positive FDA feedback on Phase 2 clinical study design for AT278 in an AID system
News
-
29/09/2025
Executive and Non-Executive Board Changes
-
25/09/2025
Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million
-
04/09/2025
Arecor announces positive FDA feedback on Phase 2 clinical study design for AT278 in an AID system
-
14/07/2025
ARECOR ESTABLISHES NEW SCIENTIFIC ADVISORY BOARD OF WORLD LEADING EXPERTS IN ORAL DRUG DELIVERY
-
19/05/2025
ARECOR ESTABLISHES PARTNERSHIP WITH SKYE BIOSCIENCE TO DEVELOP ENHANCED FORMULATION OF OBESITY CANDIDATE NIMACIMAB
-
08/05/2025
ARECOR SELLS RIGHTS TO NON-OGLUO® PRODUCTS
-
26/03/2025
ARECOR ENTERS COLLABORATION WITH MAJOR GLOBAL PHARMACEUTICAL PARTNER
-
12/03/2025
ARECOR ESTABLISHES PARTNERSHIP WITH BIOPHARMACEUTICAL COMPANY TO DEVELOP NOVEL FORMULATION OF PEPTIDE THERAPY